First time in Human Study of AZD8701 with or without Durvalumab in Participants with Advanced Solid Tumours

Study identifier:D9950C00001

ClinicalTrials.gov identifier:NCT04504669

EudraCT identifier:2019-004539-22

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination with Durvaluamb (MEDI4736) in Participants with Advanced Solid Tumours.

Medical condition

Clear Cell Renal Cell Cancer

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD8701

Sex

All

Actual Enrollment

60

Study type

Interventional

Age

18 Years - 101 Years

Date

Study Start Date: 18 Aug 2020
Estimated Primary Completion Date: 31 Jan 2025
Estimated Study Completion Date: 31 Jan 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria